Literature DB >> 6832764

Pulmonary blastomycosis: filamentous forms in an immunocompromised patient with fulminating respiratory failure.

J B Atkinson, T L McCurley.   

Abstract

A 72-year-old woman with Sjögren's syndrome manifested acute fulminating respiratory failure and was treated with high-dose corticosteroids. Autopsy revealed overwhelming pulmonary infection by Blastomyces dermatitidis with no evidence of extrapulmonary dissemination. Hyphal forms, usually not observed in vivo, were noted in premortem sputum samples as well as in sections of lung obtained at autopsy. It is proposed that the immunocompromised state of the patient played a pathogenetic role in the fulminating clinical course as well as in the production of filamentous forms of B. dermatitidis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832764     DOI: 10.1016/s0046-8177(83)80250-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Primary cutaneous blastomycosis as a cause of acute respiratory distress syndrom: case report and literature review.

Authors:  Jason J Emer; Joel B Spear
Journal:  J Clin Aesthet Dermatol       Date:  2009-03

2.  Paracoccidioidomycosis in nude mice: presence of filamentous forms of the fungus.

Authors:  I B Kerr; A M Mendes da Silva; E Drouhet; P de Oliveira; S C da Costa
Journal:  Mycopathologia       Date:  1988-01       Impact factor: 2.574

3.  Clinical characteristics and outcomes in patients with pulmonary blastomycosis.

Authors:  Doug Kralt; Bruce Light; Mary Cheang; Tracy MacNair; Lyle Wiebe; Bill Limerick; Pete Sarsfield; Greg Hammond; Kerry MacDonald; Elly Trepman; John M Embil
Journal:  Mycopathologia       Date:  2008-10-19       Impact factor: 2.574

4.  Interaction of Blastomyces dermatitidis, Sporothrix schenckii, and Histoplasma capsulatum with Acanthamoeba castellanii.

Authors:  Judith N Steenbergen; Joshua D Nosanchuk; Stephanie D Malliaris; Arturo Casadevall
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.